Увійти

Готові списки джерел за темами / AS03 / Статті в журналах

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: AS03.

Статті в журналах з теми "AS03"

Автор: Grafiati

Опубліковано: 3 червня 2025

Оновлено: 31 липня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "AS03".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Guardado-Fierros, Beatriz Genoveva, Miguel Angel Lorenzo-Santiago, Thiago Gumiere, Lydia Aid, Jacobo Rodriguez-Campos, and Silvia Maribel Contreras-Ramos. "Glyphosate Biodegradation by Airborne Plant Growth-Promoting Bacteria: Influence on Soil Microbiome Dynamics." Agriculture 15, no. 4 (2025): 362. https://doi.org/10.3390/agriculture15040362.

Повний текст джерела

Анотація:

Due to its persistence, glyphosate contamination in soil poses environmental and health risks. Plant growth-promoting bacteria (PGPB) offer a potential solution for mitigating glyphosate pollution. This study assessed the glyphosate degradation capacity of three airborne PGPB isolates (Exiguobacterium indicum AS03, Kocuria sediminis AS04, and Rhodococcus rhodochrous AS33) individually and in a consortium (CS) compared to natural attenuation in microcosms as the control (CTL), where soil autochthonous microorganisms (MS) were present. AS03 exhibited the highest glyphosate degradation (86.3%), f

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Yam, Karen, Angela Brewer, Jyotsana Gupta, Elizabeth Allen, and Brian Ward. "Long-term immune responses to AS03-adjuvanted, low antigen dose influenza vaccines in BALB/c mice (P4299)." Journal of Immunology 190, no. 1_Supplement (2013): 123.13. http://dx.doi.org/10.4049/jimmunol.190.supp.123.13.

Повний текст джерела

Анотація:

Abstract During the 2009 pandemic influenza outbreak, a vaccine formulated with the oil-in-water adjuvant AS03 and 25% of the usual antigen dose was selected for administration to Canadians. Since the long-term (LT) immune response to this vaccine remains unclear, our objective is to study AS03-adjuvanted low antigen dose influenza vaccines in mice with a focus on LT immunity. We hypothesize that LT memory following unadjuvanted full-dose vaccine will be superior to adjuvanted low-dose vaccination. Mice received 2 IM injections of influenza A/Uruguay H3N2 split vaccine formulated with 3µg anti

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Rambe, Dirga Sakti, Giuseppe Del Giudice, Stefania Rossi, and Melvin Sanicas. "Safety and Mechanism of Action of Licensed Vaccine Adjuvants." International Current Pharmaceutical Journal 4, no. 8 (2015): 420–31. http://dx.doi.org/10.3329/icpj.v4i8.24024.

Повний текст джерела

Анотація:

Vaccines are some of the most effective tools for the prevention of infectious diseases. Adjuvants are included in vaccines for a variety of reasons: to increase the breadth of response, to lower antigen dose, to overcome limited immune response in some populations, or to enable complex combination vaccines. This study aims to review the safety of licensed vaccine adjuvants and describe their mechanism of action. Potential publications for inclusion were identified through a direct search of PubMed/Medline database. Results of online literature searches were supplemented by relevant papers cit

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Dai, MingRui, XueJian Feng, ZengShuo Mo та ін. "Stimulation Effects and Mechanisms of Different Adjuvants on a Norovirus P Particle-Based Active Amyloid-β Vaccine". Journal of Alzheimer's Disease 77, № 4 (2020): 1717–32. http://dx.doi.org/10.3233/jad-200351.

Повний текст джерела

Анотація:

Background: Adjuvants are important components of vaccines and effectively enhance the immune response of specific antigens. However, the role of adjuvants or combinations of adjuvants in stimulating immunogenicity of the amyloid-β (Aβ) vaccine, as well as molecular mechanisms underlying such stimulation still remain unclear. A previous study of ours developed a norovirus P particle-based active Aβ epitope vaccine, PP-3copy-Aβ1-6-loop123, which stimulates a high titer of Aβ-specific antibodies in mouse Alzheimer’s disease (AD) models. Objective: The most effective and safe adjuvant that maximi

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Hidayat, Asep, and Sanro Tachibana. "DECOLORIZATION OF AZO DYES AND MINERALIZATION OF PHENANTHRENE BY TRAMETES SP. AS03 ISOLATED FROM INDONESIAN MANGROVE FOREST." JOURNAL OF FORESTRY RESEARCH 1, no. 1 (2014): 67–75. https://doi.org/10.20886/ijfr.2014.1.1.67-75.

Повний текст джерела

Анотація:

Textile industry contributes the most disposals of synthetic dyes, and about 40% of textile dyes has been generating high amount of colored wastewater. Polycyclic aromatic hydrocarbons (PAHs), such as phenanthrene, is a group of organic compounds, that structurally comprised of two or more benzene rings, which persist in air, water, and soil. The organic pollutants of dyes and PAHs have adversely effects the food chain and are potentially toxic, mutagenic, and carcinogenic to the environment. The objective of this research is to screen and investigate the potential fungus from mangrove forest

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Hidayat, Asep, and Sanro Tachibana. "DECOLORIZATION OF AZO DYES AND MINERALIZATION OF PHENANTHRENE BY TRAMETES SP. AS03 ISOLATED FROM INDONESIAN MANGROVE FOREST." Indonesian Journal of Forestry Research 1, no. 1 (2014): 67–75. https://doi.org/10.59465/ijfr.2014.1.1.67-75.

Повний текст джерела

Анотація:

Textile industry contributes the most disposals of synthetic dyes, and about 40% of textile dyes has been generating high amount of colored wastewater. Polycyclic aromatic hydrocarbons (PAHs), such as phenanthrene, is a group of organic compounds, that structurally comprised of two or more benzene rings, which persist in air, water, and soil. The organic pollutants of dyes and PAHs have adversely effects the food chain and are potentially toxic, mutagenic, and carcinogenic to the environment. The objective of this research is to screen and investigate the potential fungus from mangrove forest

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Chen, Wilbur H., Lisa A. Jackson, Kathryn M. Edwards, et al. "Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant." Clinical and Vaccine Immunology 23, no. 1 (2015): 73–77. http://dx.doi.org/10.1128/cvi.00475-15.

Повний текст джерела

Анотація:

ABSTRACTThe adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends those findings to 1 year after vaccination.

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Bradford, A. "Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes." Leukemia Research 108 (September 2021): 106681.12. http://dx.doi.org/10.1016/j.leukres.2021.106681.12.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Dubow, J., A. Guerci, E. Gyan, and A. Dupuis-Sireva. "Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes." Leukemia Research 108 (September 2021): 106681.13. http://dx.doi.org/10.1016/j.leukres.2021.106681.13.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Kota, V., A. Ogbonnaya, E. Farrelly, et al. "Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care." Leukemia Research 108 (September 2021): 106681.11. http://dx.doi.org/10.1016/j.leukres.2021.106681.11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Haring, Y., H. S. Oster, A. Kolomansky, N. Cohen Sagy, and M. Mittelman. "Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes." Leukemia Research 108 (September 2021): 106681.14. http://dx.doi.org/10.1016/j.leukres.2021.106681.14.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Zeidan, A. M., N. Joshi, H. Kale, et al. "Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care." Leukemia Research 108 (September 2021): 106681.10. http://dx.doi.org/10.1016/j.leukres.2021.106681.10.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Pillet, Stéphane, Prabhu S. Arunachalam, Guadalupe Andreani, et al. "Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates." Cellular & Molecular Immunology 19, no. 2 (2022): 222–33. http://dx.doi.org/10.1038/s41423-021-00809-2.

Повний текст джерела

Анотація:

AbstractAlthough antivirals are important tools to control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, effective vaccines are essential to control the current coronavirus disease 2019 (COVID-19) pandemic. Plant-derived virus-like particle (VLP) vaccine candidates have previously demonstrated immunogenicity and efficacy against influenza. Here, we report the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a VLP bearing a SARS-CoV-2 spike protein (CoVLP) vaccine candidate formulated with or without Adjuvant System 03 (AS03) or c

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Yam, Karen, Jyotsana Gupta, Elizabeth Allen, and Brian Ward. "Adjuvanted influenza vaccines in young and aged BALB/c mice (166.25)." Journal of Immunology 188, no. 1_Supplement (2012): 166.25. http://dx.doi.org/10.4049/jimmunol.188.supp.166.25.

Повний текст джерела

Анотація:

Abstract Although the available influenza vaccines are generally safe, they are far from ideal. They have reduced efficacy in the most at risk groups: the very young and the elderly. To address such concerns, the vaccine industry is increasingly turning its attention to the use of adjuvants to enhance the immune responses generated by these vaccines. During the 2009 pandemic H1N1 influenza outbreak, an adjuvanted influenza vaccine was selected for administration to Canadians; it was formulated with the oil-in-water adjuvant AS03 and consisted of 1/4 the usual antigen dose of vaccine. This stud

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Li, Zhuofan, Yiwen Zhao, Yibo Li, and Xinyuan Chen. "Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity." Vaccines 9, no. 2 (2021): 75. http://dx.doi.org/10.3390/vaccines9020075.

Повний текст джерела

Анотація:

Influenza poses a huge threat to global public health. Influenza vaccines are the most effective and cost-effective means to control influenza. Current influenza vaccines mainly induce neutralizing antibodies against highly variable globular head of hemagglutinin and lack cross-protection. Vaccine adjuvants have been approved to enhance seasonal influenza vaccine efficacy in the elderly and spare influenza vaccine doses. Clinical studies found that MF59 and AS03-adjuvanted influenza vaccines could induce cross-protective immunity against non-vaccine viral strains. In addition to MF59 and AS03

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Lodaya, Rushit N., Amey P. Kanitkar, Asma Ashraf, Douty Bamba, Mansoor M. Amiji, and Derek T. O’Hagan. "A Self-Emulsified Adjuvant System Containing the Immune Potentiator Alpha Tocopherol Induces Higher Neutralizing Antibody Responses than a Squalene-Only Emulsion When Evaluated with a Recombinant Cytomegalovirus (CMV) Pentamer Antigen in Mice." Pharmaceutics 15, no. 1 (2023): 238. http://dx.doi.org/10.3390/pharmaceutics15010238.

Повний текст джерела

Анотація:

The development of new vaccine adjuvants represents a key approach to improvingi the immune responses to recombinant vaccine antigens. Emulsion adjuvants, such as AS03 and MF59, in combination with influenza vaccines, have allowed antigen dose sparing, greater breadth of responses and fewer immunizations. It has been demonstrated previously that emulsion adjuvants can be prepared using a simple, low-shear process of self-emulsification (SE). The role of alpha tocopherol as an immune potentiator in emulsion adjuvants is clear from the success of AS03 in pandemic responses, both to influenza and

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Howard, Leigh, Johannes Goll, Travis Jensen, et al. "994. AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Peripheral Blood Mononuclear Cells." Open Forum Infectious Diseases 5, suppl_1 (2018): S295—S296. http://dx.doi.org/10.1093/ofid/ofy210.831.

Повний текст джерела

Анотація:

Abstract Background Influenza A/H5N1 vaccines have been poorly immunogenic. Addition of Adjuvant System 03 (AS03) markedly enhances immune responses, but the mechanisms of this enhancement are unclear. Methods We compared gene expression in peripheral blood mononuclear cells (PBMCs) between recipients of AS03-adjuvanted and unadjuvanted inactivated split-virus H5N1 vaccine on days 1, 3, 7, and 28 postvaccination. We used a systems vaccinology approach to assess functional classifications of differentially expressed (DE) genes between the two vaccine groups, identify DE genes that correlate wit

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Francica, Joseph R., Barbara J. Flynn, Kathryn E. Foulds, et al. "Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates." Science Translational Medicine 13, no. 607 (2021): eabi4547. http://dx.doi.org/10.1126/scitranslmed.abi4547.

Повний текст джерела

Анотація:

Adjuvanted soluble protein vaccines have been used extensively in humans for protection against various viral infections based on their robust induction of antibody responses. Here, soluble prefusion-stabilized spike protein trimers (preS dTM) from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were formulated with the adjuvant AS03 and administered twice to nonhuman primates (NHPs). Binding and functional neutralization assays and systems serology revealed that the vaccinated NHP developed AS03-dependent multifunctional humoral responses that targeted distinct domains of the spi

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Ledgerwood, Julie E. "AS03-adjuvanted influenza vaccine in elderly people." Lancet Infectious Diseases 13, no. 6 (2013): 466–67. http://dx.doi.org/10.1016/s1473-3099(13)70038-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Baz, Mariana, Mukesh Samant, Hakima Zekki, et al. "Effects of Different Adjuvants in the Context of Intramuscular and Intranasal Routes on Humoral and Cellular Immune Responses Induced by Detergent-Split A/H3N2 Influenza Vaccines in Mice." Clinical and Vaccine Immunology 19, no. 2 (2011): 209–18. http://dx.doi.org/10.1128/cvi.05441-11.

Повний текст джерела

Анотація:

ABSTRACTInfluenza A/H3N2 viruses have caused the most severe epidemics since 1968 despite current immunization programs with inactivated vaccines. We undertook a side-by-side preclinical evaluation of different adjuvants (Alum, AS03, and Protollin) and routes of administration (intramuscular [i.m.] and intranasal [i.n.]) for assessing their effect on the immunogenicity and cross-reactivity of inactivated split vaccines (A/H3N2/New York/55/2004). Humoral and T cell-mediated immune responses against the homologous virus and a heterologous drifted strain (A/H3N2/Wisconsin/67/2005) were measured i

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Berglund, Johan, Peter Vink, Fernanda Tavares Da Silva, Pascal Lestrate, and Dominique Boutriau. "Safety, Immunogenicity, and Antibody Persistence following an Investigational Streptococcus pneumoniae and Haemophilus influenzae Triple-Protein Vaccine in a Phase 1 Randomized Controlled Study in Healthy Adults." Clinical and Vaccine Immunology 21, no. 1 (2013): 56–65. http://dx.doi.org/10.1128/cvi.00430-13.

Повний текст джерела

Анотація:

ABSTRACTWe investigated a protein-based nontypeableHaemophilus influenzae(NTHi) and pneumococcal (HiP) vaccine containing pneumococcal histidine triad D (PhtD), detoxified pneumolysin (dPly), and NTHi protein D (PD) in adults. In a phase I study, 40 healthy 18- to 40-year-old subjects were randomized (2:2:1) to receive two HiP doses administered 60 days apart, with or without AS03 adjuvant (HiP-AS and HiP groups, respectively), or Engerix B (GlaxoSmithKline, Belgium) as a control. Safety, antibodies, and antigen-specific CD4+T-cell immune responses were assessed before and until 480 days after

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Nakkala, Jayachandra Reddy, Yibo Li, Labone Akter, Xinliang Kang, and Xinyuan Chen. "Differential Regulation of DC Function, Adaptive Immunity, and MyD88 Dependence by MF59 and AS03-like Adjuvants." Vaccines 12, no. 5 (2024): 531. http://dx.doi.org/10.3390/vaccines12050531.

Повний текст джерела

Анотація:

MF59 and AS03 are squalene emulsion-based vaccine adjuvants with similar compositions and droplet sizes. Despite their broad use in licensed influenza vaccines, few studies compared their adjuvant effects and action mechanisms side by side. Considering the majority of adjuvants act on dendritic cells (DCs) to achieve their adjuvant effects, this study compared MF59 and AS03-like adjuvants (AddaVax and AddaS03, respectively) to enhance antigen uptake, DC maturation, ovalbumin (OVA) and seasonal influenza vaccine-induced immune responses. Considering MF59 was reported to activate MyD88 to mediat

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Ward, Brian J., Philipe Gobeil, Annie Séguin, et al. "Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19." Nature Medicine 27, no. 6 (2021): 1071–78. http://dx.doi.org/10.1038/s41591-021-01370-1.

Повний текст джерела

Анотація:

AbstractSeveral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being deployed, but the global need greatly exceeds the supply, and different formulations might be required for specific populations. Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004). The co-primary outcomes were the short-term tolerability/safety and immunogenicity of CoVLP formulations assess

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Ellebedy, Ali H., Raffael Nachbagauer, Katherine J. L. Jackson, et al. "Adjuvanted H5N1 influenza vaccine enhances both cross-reactive memory B cell and strain-specific naive B cell responses in humans." Proceedings of the National Academy of Sciences 117, no. 30 (2020): 17957–64. http://dx.doi.org/10.1073/pnas.1906613117.

Повний текст джерела

Анотація:

There is a need for improved influenza vaccines. In this study we compared the antibody responses in humans after vaccination with an AS03-adjuvanted versus nonadjuvanted H5N1 avian influenza virus inactivated vaccine. Healthy young adults received two doses of either formulation 3 wk apart. We found that AS03 significantly enhanced H5 hemagglutinin (HA)-specific plasmablast and antibody responses compared to the nonadjuvanted vaccine. Plasmablast response after the first immunization was exclusively directed to the conserved HA stem region and came from memory B cells. Monoclonal antibodies (

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Coirada, Fernanda Caroline, Edgar Ruz Fernandes, Lucas Rodrigues de Mello, et al. "Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity." International Journal of Molecular Sciences 24, no. 13 (2023): 10517. http://dx.doi.org/10.3390/ijms241310517.

Повний текст джерела

Анотація:

Chikungunya virus (CHIKV) has become a significant public health concern due to the increasing number of outbreaks worldwide and the associated comorbidities. Despite substantial efforts, there is no specific treatment or licensed vaccine against CHIKV to date. The E2 glycoprotein of CHIKV is a promising vaccine candidate as it is a major target of neutralizing antibodies during infection. In this study, we evaluated the immunogenicity of two DNA vaccines (a non-targeted and a dendritic cell-targeted vaccine) encoding a consensus sequence of E2CHIKV and a recombinant protein (E2*CHIKV). Mice w

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Santini, V., R. Bejar, C. Belli, et al. "Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS ?" Leukemia Research 128 (May 2023): 107164. http://dx.doi.org/10.1016/j.leukres.2023.107164.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Walker, Woolf T., and Saul N. Faust. "Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine." Expert Review of Vaccines 9, no. 12 (2010): 1385–98. http://dx.doi.org/10.1586/erv.10.141.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Cohet, Catherine, Robbert van der Most, Vincent Bauchau, et al. "Safety of AS03-adjuvanted influenza vaccines: A review of the evidence." Vaccine 37, no. 23 (2019): 3006–21. http://dx.doi.org/10.1016/j.vaccine.2019.04.048.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Javelle, Emilie, Benjamin Soulier, Christian Brosset, Solène Lorcy, and Fabrice Simon. "Delayed focal lipoatrophy after AS03-adjuvanted influenza A (H1N1) 2009 vaccine." Vaccine 29, no. 6 (2011): 1123–25. http://dx.doi.org/10.1016/j.vaccine.2010.12.018.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Goethals, K. "AS03-02 - Reactions and consequences following ECHR judgements in the Netherlands." European Psychiatry 27 (January 2012): 1. http://dx.doi.org/10.1016/s0924-9338(12)73959-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Baldwin, Susan, Sylvie Bertholet, Valerie Reese, Lance Ching, Steven Reed, and Rhea Coler. "Modulation of protection against Mycobacterium tuberculosis by adjuvants that elicit different T cell responses. (166.18)." Journal of Immunology 188, no. 1_Supplement (2012): 166.18. http://dx.doi.org/10.4049/jimmunol.188.supp.166.18.

Повний текст джерела

Анотація:

Abstract The use of an adjuvant within a vaccine can influence and direct the immune response to enable a desired outcome. A T helper 1 (Th1) response, including antigen-specific production of interferon-gamma (IFN-γ), is needed to protect against Mycobacterium tuberculosis. A successful subunit vaccine should include not only an appropriate antigen but also a proper adjuvant to ensure that a Th1 mediated cellular response is induced. Only a few adjuvants have been approved for use in human vaccines such as Alum and oil-in-water (o/w) based emulsions, including MF59 (Novartis), AS03 (GSK Biolo

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Abdul Nabi, Y. Z. Ahmed, A. N. Jatt, et al. "INVESTIGATION OF N-ACYL HOMOSERINE LACTONE-BASED QUORUM-SENSING SYSTEM AND ALIGINATE LYASE ACTIVITY IN MARINE BACTERIAL SPECIES OF GRIMONTIA MARINA AS01 AND ALTEROMONAS MACLEODII AS02." Pakistan Journal of Science 74, no. 1-1 (2023): 25–31. http://dx.doi.org/10.57041/pjs.v74i1-1.905.

Повний текст джерела

Анотація:

Production, detection, and reaction to external signaling molecules are essential steps in quorum sensing (QS) process. Through the use of QS, bacterial communities may synchronize their responses to shifts in the density and diversity of their vicinal neighbors. QS also play an important role in regulating enzmyatic activities among marine bacteria. The aim of the present study was to detect and identify N- acyl homoserine lactones (AHLs) based QS signaling molecules and the possible influence on alginate lyase in marine bacterial isolates of Grimontia marina AS01 and Alteromonas macleodi AS0

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Yam, Karen K., Jyotsana Gupta, Angela Brewer, David W. Scheifele, Scott Halperin, and Brian J. Ward. "Unusual Patterns of IgG Avidity in Some Young Children following Two Doses of the Adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine." Clinical and Vaccine Immunology 20, no. 4 (2013): 459–67. http://dx.doi.org/10.1128/cvi.00619-12.

Повний текст джерела

Анотація:

ABSTRACTDuring the 2009-2010 H1N1 influenza pandemic, an adjuvanted monovalent vaccine containing ∼25% of the normal antigen dose and AS03 adjuvant was widely used in Canada. This vaccine was found to be well-tolerated and immunogenic in young children (D. W. Scheifele et al., Pediatr. Infect. Dis. J. 30:402–407, 2011). We report here additional analyses to further characterize the humoral response to this vaccine. We measured standard hemagglutination inhibition (HAI) and microneutralization (MN) titers, as well as influenza virus-specific IgG avidity and subclass distribution by enzyme-linke

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Thebault, Simon, Patrick Waters, Matthew D. Snape, et al. "Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination." PLOS ONE 10, no. 6 (2015): e0129555. http://dx.doi.org/10.1371/journal.pone.0129555.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Lam, Joseph M. "Atypical Gianotti-Crosti syndrome following administration of the AS03-adjuvanted H1N1 vaccine." Journal of the American Academy of Dermatology 65, no. 4 (2011): e127-e128. http://dx.doi.org/10.1016/j.jaad.2011.04.005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

De Serres, Gaston, Marie-Claude Gariépy, Brenda Coleman, et al. "Short and Long-Term Safety of the 2009 AS03-Adjuvanted Pandemic Vaccine." PLoS ONE 7, no. 7 (2012): e38563. http://dx.doi.org/10.1371/journal.pone.0038563.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Segal, Lawrence, Sandrine Wouters, Danielle Morelle, et al. "Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines." Journal of Applied Toxicology 35, no. 12 (2015): 1564–76. http://dx.doi.org/10.1002/jat.3130.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Zhong, Weimin, and Min Z. Levine. "Stockpiled Avian Influenza A(H7N9) Vaccines Induce Robust, Nonneutralizing Functional Antibodies Against Antigenically Drifted Fifth-Wave A(H7N9) Viruses." Journal of Infectious Diseases 220, no. 8 (2019): 1276–80. http://dx.doi.org/10.1093/infdis/jiz295.

Повний текст джерела

Анотація:

Abstract Human infections caused by avian influenza A(H7N9) viruses have raised concerns of a pandemic. The capability of the current stockpiled A(H7N9) vaccines to induce cross-protective, nonneutralizing functional antibodies against antigenically drifted A(H7N9) viruses has not been evaluated before. Here we show that vaccination with either MF59- or AS03-adjuvanted inactivated A(H7N9) vaccines elicited robust, cross-reactive antibody-dependent cell-mediated cytotoxicity–mediating and neuraminidase-inhibiting functional antibodies against the antigenically drifted A(H7N9) viruses that emerg

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Stauder, R., A. Luehring, S. Tipelius, G. Rumpold, and P. Künstner. "Topic: AS03-Health Economics & Outcome Research/AS03b-Patient-reported outcomes: IMPLEMENTATION AND USE OF ELECTRONIC PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS." Leukemia Research 128 (May 2023): 107166. http://dx.doi.org/10.1016/j.leukres.2023.107166.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Siegrist, Claire-Anne, Juan Ambrosioni, Michael Bel, et al. "Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine." Antiviral Therapy 17, no. 5 (2012): 893–903. http://dx.doi.org/10.3851/imp2103.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Garcia-Sicilia, J., P. Gillard, A. Carmona, et al. "Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents." Vaccine 29, no. 26 (2011): 4353–61. http://dx.doi.org/10.1016/j.vaccine.2011.04.011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Galassie, Allison C., Johannes B. Goll, Parimal Samir, et al. "Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination." PROTEOMICS 17, no. 12 (2017): 1600453. http://dx.doi.org/10.1002/pmic.201600453.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Fujiwara, Ricardo T., Bin Zhan, Susana Mendez, et al. "Reduction of Worm Fecundity and Canine Host Blood Loss Mediates Protection against Hookworm Infection Elicited by Vaccination with Recombinant Ac-16." Clinical and Vaccine Immunology 14, no. 3 (2007): 281–87. http://dx.doi.org/10.1128/cvi.00404-06.

Повний текст джерела

Анотація:

ABSTRACT Hookworm infection is one of most important parasitic infection of humans, occurring in 740 million people. Here we report the protective vaccination of dogs with Ac-16, an immunodominant surface antigen from the hookworm Ancylostoma caninum. We show that immunization with Ac-16 formulated with AS03 elicited specific humoral and cellular immune responses and provided partial protection against hookworm infection and morbidity as evidenced by a significant reduction of hookworm egg counts (64% reduction; P = 0.0078) and worm-induced blood loss (P < 0.05). Moreover, specific anti-Ac-

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Castelo, L., C. Belli, V. Buccheri, et al. "Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care: ALTERNATIVE DOSING SCHEDULES OF AZACITIDINE: A REAL-WORLD COMPARATIVE STUDY ACROSS SOUTH AMERICAN CENTERS." Leukemia Research 128 (May 2023): 107165. http://dx.doi.org/10.1016/j.leukres.2023.107165.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Boquete Castro, A., and J. M. Cortés Mejía. "Vacuna frente a influenza H1N1 con adyuvante AS03 y su efecto desencadenante de narcolepsia." Vacunas 22, no. 2 (2021): 119–24. http://dx.doi.org/10.1016/j.vacun.2020.09.006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Jacob, Louis, Ryan Leib, Hanna M. Ollila, Mélodie Bonvalet, Christopher M. Adams, and Emmanuel Mignot. "Comparison of Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with narcolepsy development." Brain, Behavior, and Immunity 47 (July 2015): 44–57. http://dx.doi.org/10.1016/j.bbi.2014.11.004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Manuel, O., M. Pascual, K. Hoschler, et al. "Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients." Clinical Infectious Diseases 52, no. 2 (2010): 248–56. http://dx.doi.org/10.1093/cid/ciq104.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Nazareth, Irwin, Fernanda Tavares, Dominique Rosillon, François Haguinet, and Vincent Bauchau. "Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study." BMJ Open 3, no. 2 (2013): e001912. http://dx.doi.org/10.1136/bmjopen-2012-001912.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Sengler, C., M. Niewerth, T. Kallinich, et al. "Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases." Clinical Rheumatology 33, no. 1 (2013): 137–39. http://dx.doi.org/10.1007/s10067-013-2435-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Galassie, Allison C., Johannes B. Goll, Parimal Samir, et al. "Front Cover: Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination." PROTEOMICS 17, no. 12 (2017): 1770101. http://dx.doi.org/10.1002/pmic.201770101.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!